A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

• Status: Completed
• Trial end date: 1969-12-31

Summary

The purpose of this study is to assess the antitumor activity of ALIMTA plus Oxaliplatin combination therapy in patients with previously untreated advanced colorectal cancer

• Phase: Phase 2

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Oxaliplatin; Pemetrexed